These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16080496)

  • 1. Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin.
    Takigawa N; Takeuchi M; Shibayama T; Yoshida I; Kawata N; Tada A; Ueoka H; Takahashi K
    Anticancer Res; 2005; 25(3c):2579-82. PubMed ID: 16080496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
    Suzushima H; Wada N; Yamasaki H; Eto K; Shimomura T; Kugimiya MH; Horikawa K; Nishimura S; Tsuda H; Mitsuya H; Asou N
    Leuk Res; 2010 May; 34(5):610-4. PubMed ID: 19744710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults.
    Yamada K; Mizusawa M; Harima A; Kajiwara K; Hamaki T; Hoshi K; Kozai Y; Kodo H
    Eur J Haematol; 2006 Oct; 77(4):345-8. PubMed ID: 16930144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
    Tatetsu H; Matsuno F; Takatsu N; Miyake H; Hoshino K; Nosaka K; Horikawa K; Hata H; Mitsuya H; Asou N
    Leuk Res; 2009 Jan; 33(1):197-200. PubMed ID: 18472159
    [No Abstract]   [Full Text] [Related]  

  • 7. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
    Caballero MD; González M; Cañizo MC; Orfao A; Nieto MJ; San Miguel JF
    Leukemia; 1992 Aug; 6(8):856-8. PubMed ID: 1640739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
    Pagano L; Mele L; Voso MT; Chiusolo P; Putzulu R; Mazzotta S; Leone G
    Haematologica; 2001 Apr; 86(4):440-1. PubMed ID: 11325656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The current chemotherapy of acute myeloid leukemias in adults].
    Poddubnaia IV; Perilov AA
    Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis.
    Kobayashi S; Sakai H; Tomiazwa T; Koiso H; Kim K; Ueki K; Tamura J; Yano S; Naruse T; Karasawa M
    J Med; 1999; 30(1-2):101-9. PubMed ID: 10515246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
    Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
    Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
    Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
    Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
    Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Sarno E; Frei E
    Leukemia; 1992; 6 Suppl 2():66-7. PubMed ID: 1578945
    [No Abstract]   [Full Text] [Related]  

  • 16. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
    Saito K
    Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
    Milton DT; Riely GJ; Azzoli CG; Gomez JE; Heelan RT; Kris MG; Krug LM; Pao W; Pizzo B; Rizvi NA; Miller VA
    Cancer; 2007 Aug; 110(3):599-605. PubMed ID: 17577220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
    Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
    Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.